Treatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Korea
et al., medRxiv,
Treatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First..
, medRxiv, doi:10.1101/2020.05.13.20094193 (Preprint)
Retrospective of 97 moderate cases. Time to viral clearance significantly shorter for HCQ+antibiotic. Preprint withdrawn pending peer review.
hospitalization time, 51.0% lower, relative time 0.49, p = 0.01, treatment 22, control 40.
time to viral-, 56.0% lower, relative time 0.44, p = 0.005, treatment 22, control 40.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kim et al., 18 May 2020, retrospective, South Korea, preprint, 11 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.05.13.20094193; this version posted June 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir,
and Antibiotics for Moderate COVID-19: A First Report on the
Pharmacological Outcomes from South Korea
Min Seo Kim, MD, Soon-Woo Jang, MD, KMD, Yu-Kyung Park, MD, Bong-Ok Kim, MD,
PhD, Tae-Ho Hwang, DSS, PhD, Seok Ho Kang, MD9, PhD, Won Jun Kim, MD, Park Sung
Kyu, MD, Hea-Woon Park, MD, PhD, Wonjong Yang, MD, Joonyoung Jang, MD, Min Ho
The authors have withdrawn this manuscript because of the controversy about
hydroxychloroquine and potential changes in results after peer-review, the authors intend to
share their results in formal publication. Therefore, the authors do not wish this work to be
cited as reference for the project. If you have any questions, please contact the corresponding
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.